TCR2 Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors that utilize the full signaling power of complete T cell receptors (TCR). TCR2 has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to elicit rapid killing of cancer cells with persistence and low cytokine release. The company has demonstrated superior activity against several tumor targets in preclinical models compared to CAR T cells and will advance its lead program TC-210 into the clinic in 2018.
TCR2 was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA.